Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness

Clinical Colorectal Cancer

Volumn 15, Issue 3, 2016, Pages e65-e74

  Berger, Barry M ^a   Schroy, Paul C ^b   Dinh, Tuan A ^c  

^a Exact Sciences Corporation   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Archimedes Inc   (United States)

Author keywords

Archimedes; Colonoscopy; Guidelines; Model; Utility

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLONOSCOPE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DNA DETERMINATION; FECES ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; MULTITARGET STOOL DNA TEST; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; BIOLOGICAL MODEL; CHEMISTRY; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; FECES; MASS SCREENING; PROCEDURES; THEORETICAL MODEL;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DNA; EARLY DETECTION OF CANCER; FECES; HUMANS; MASS SCREENING; MODELS, BIOLOGICAL; MODELS, THEORETICAL;

EID: 84953775029     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.12.003     Document Type: Article

References (118)

1. 1 Agency for Healthcare Research and Quality, Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 149 (2008), 627–637.
2. 2 Centers for Disease Control and Prevention, Cancer screening–United States, 2010. MMWR Morb Mortal Wkly Rep 61 (2012), 41–45.
3. 3 Taylor, D.P., Cannon-Albright, L.A., Sweeney, C., et al. Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med 13 (2011), 737–743.
4. 4 Kaminski, M.F., Regula, J., Kraszewska, E., et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 362 (2010), 1795–1803.
5. 5 Kahi, C.J., Hewett, D.G., Norton, D.L., Eckert, G.J., Rex, D.K., Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol 9 (2011), 42–46.
6. 6 Berger, B.M., Ahlquist, D.A., Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology 44 (2012), 80–88.
7. 7 Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370 (2014), 1287–1297.
8. 8 Lidgard, G.P., Domanico, M.J., Bruinsma, J.J., et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 11 (2013), 1313–1318.
9. 9 Rex, D.K., Johnson, D.A., Anderson, J.C., et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 104 (2009), 739–750.
10. 10 Levin, B., Lieberman, D.A., McFarland, B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134 (2008), 1570–1595.
11. 11 Agency for Healthcare Research and Quality. Fecal DNA testing in screening for colorectal cancer in average-risk adults. 2012. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/282/988/CER52_Fecal-DNA-Testing_20120229.pdf. Accessed April 1, 2015.
12. 12 Dinh, T.A., Rosner, B.I., Atwood, J.C., et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 4 (2011), 9–22.
13. 13 Zauber, A.G., Landsdorp-Vogelaar, I., Wilschut, J., Knudsen, A.B., van Ballegooijen, M., Kuntz, K.M., Cost-effectiveness of DNA stool testing to screen for colorectal cancer. 2007, Agency for Healthcare Research and Quality (US), Rockville, MD Available at: http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id52TA.pdf Accessed April 1, 2015.
14. 14 Gellad, Z.F., Stechuchak, K.M., Fisher, D.A., et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol 106 (2011), 1125–1134.
15. 15 Inadomi, J.M., Vijan, S., Janz, N.K., et al. Adherence to colorectal screening: a randomized clinical trial of competing strategies. Arch Intern Med 172 (2012), 575–582.
16. 16 Fenton, J.J., Elmore, J.G., Buist, D.S., Reid, R.J., Tancredi, D.J., Baldwin, L.M., Longitudinal adherence with fecal occult blood test screening in community practice. Ann Fam Med 8 (2010), 397–401.
17. 17 Janda, M., Hughes, K.L., Auster, J.F., Leggett, B.A., Newman, B.M., Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: a community-based project in a rural setting. J Gastroenterol Hepatol 25 (2010), 1661–1667.
18. 18 Steele, R.J., Kostourou, I., McClements, P., et al. Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening. BMJ, 341, 2010, c5531.
19. 19 Hassan, C., Giorgi Rossi, P., Camilloni, L., et al. Meta-analysis: adherence to colorectal cancer screenng and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 36 (2012), 929–940.
20. 20 Mandel, J.S., Bond, J.H., Church, T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328 (1993), 1365–1371.
21. 21 Levin, T.R., Jensen, C.D., Zhao, W., et al. Adherence to annual fecal immunochemical testing in a large community-based population. Gastroenterology 144 (2013), S145–S146.
22. 22 Schroy, P.C. III, Lal, S., Glick, J.T., Robinson, P.A., Zamor, P., Heeren, T.C., Patient preferences for colorectal cancer screening: how does stool DNA testing fare?. Am J Manag Care 13 (2007), 393–400.
23. 23 King, J.T. Jr., Tsevat, J., Lave, J.R., Roberts, M.S., Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 25 (2005), 667–677.
24. 24 van den Akker-van Marle, M.E., van Ballegooijen, M., van Oortmarssen, G.J., Boer, R., Habbema, J.D., Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 94 (2002), 193–204.
25. 25 Stout, N.K., Rosenberg, M.A., Trentham-Dietz, A., Smith, M.A., Robinson, S.M., Fryback, D.G., Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 98 (2006), 774–782.
26. 26 Berger, B.M., Schroy, P.C. III, Rosenberg, J.L., et al. Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests. Clin Colorectal Cancer 5 (2006), 338–343.
27. 27 Rex, D.K., Ahnen, D.J., Baron, J.A., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 107 (2012), 1315–1329.
28. 28 Brenner, H., Chang-Claude, J., Seiler, C.M., Rickert, A., Hoffmeister, M., Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 154 (2011), 22–30.
29. 29 Lieberman, D.A., Rex, D.K., Winawer, S.J., et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143 (2012), 844–857.
30. 30 Baxter, N.N., Goldwasser, M.A., Paszat, L.F., Saskin, R., Urbach, D.R., Rabeneck, L., Association of colonoscopy and death from colorectal cancer. Ann Intern Med 150 (2009), 1–8.
31. 31 Brenner, H., Hoffmeister, M., Arndt, V., Stegmaier, C., Altenhofen, L., Haug, U., Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 102 (2010), 89–95.
32. 32 ACS CRC screening guideline at http://www.cancer.org/cancer/colonandrectumcancer/moreinformation/colonandrectumcancerearlydetection/colorectal-cancer-early-detection-screening-tests-used. Accessed November 1, 2014.
33. 33 Centers for Medicare and Medicaid Services. Decision memo for screening for colorectal cancer–stool DNA testing (CAG-00440N). 2014. Available at: http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=277&bc=AAAAAAAAAAEAAA%3D%3D&. Accessed March 26, 2015.
34. 1 Kahn, R., Alperin, P., Eddy, D., et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375 (2010), 1365–1374.
35. 2 Schlessinger, L., Eddy, D.M., Archimedes: a new model for simulating health care systems—the mathematical formulation. J Biomed Inform 35 (2002), 37–50.
36. 3 Clinical Outcomes Research Initiative. Available at: http://www.cori.org/. Accessed December 07, 2013.
37. 4 National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: US Population Data 1969-2013. Available at: http://www.seer.cancer.gov/popdata/. Accessed April 2, 2015.
38. 5 Rutter, C.M., Yu, O., Miglioretti, D.L., A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med 26 (2007), 98–109.
39. 6 Welin, S., Youker, J., Spratt, J.S. Jr., The rates and patterns of growth of 375 tumors of the large intestine and rectum observed serially by double contrast enema study (Malmoe technique). Am J Roentgenol Radium Ther Nucl Med 90 (1963), 673–687.
40. 7 Bolin, S., Nilsson, E., Sjödahl, R., Carcinoma of the colon and rectum—growth rate. Ann Surg 198 (1983), 151–158.
41. 8 Umetani, N., Masaki, T., Watanabe, T., Sasaki, S., Matsuda, K., Muto, T., Retrospective radiographic analysis of nonpedunculated colorectal carcinomas with special reference to tumor doubling time and morphological change. Am J Gastroenterol 95 (2000), 1794–1799.
42. 9 Matsui, T., Tsuda, S., Yao, K., Iwashita, A., Sakurai, T., Yao, T., Natural history of early colorectal cancer: evolution of a growth curve. Dis Colon Rectum 43:10 suppl (2000), S18–S22.
43. 10 Winawer, S.J., Zauber, A.G., Ho, M.N., et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 329 (1993), 1977–1981.
44. 11 Winawer, S.J., Flehinger, B.J., Schottenfeld, D., Miller, D.G., Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 85 (1993), 1311–1318.
45. 12 Chao, A., Connell, C.J., Cokkinides, V., Jacobs, E.J., Calle, E.E., Thun, M.J., Underuse of screening sigmoidoscopy and colonoscopy in a large cohort of US adults. Am J Public Health 94 (2004), 1775–1781.
46. 13 Higginbotham, S., Zhang, Z.F., Lee, I.M., et al. Dietary glycemic load and risk of colorectal cancer in the Women's Health Study. J Natl Cancer Inst 96 (2004), 229–233.
47. 14 Beresford, S.A., Johnson, K.C., Ritenbaugh, C., et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (2006), 643–654.
48. 15 Atkin, W.S., Edwards, R., Kralj-Hans, I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375 (2010), 1624–1633.
49. 16 Lieberman, D.A., Weiss, D.G., Bond, J.H., et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med 343 (2000), 162–168.
50. 17 Lansdorp-Vogelaar, I., van Ballegooijen, M., Zauber, A.G., Habbema, J.D., Kuipers, E.J., Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 101 (2009), 1412–1422.
51. 18 Gross, C.P., McAvay, G.J., Krumholz, H.M., Paltiel, A.D., Bhasin, D., Tinetti, M.E., The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145 (2006), 646–653.
52. 19 Ness, R.M., Holmes, A.M., Klein, R., Dittus, R., Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 94 (1999), 1650–1657.
53. 20 Siegel, J.E., Weinstein, M.C., Russell, L.B., Gold, M.R., Recommendations for reporting cost-effectiveness analyses: panel on cost-effectiveness in health and medicine. JAMA 276 (1996), 1339–1341.
54. 1 Rutter, C.M., Yu, O., Miglioretti, D.L., A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med 26 (2007), 98–109.
55. 2 Lieberman, D.A., Holub, J.L., Moravec, M.D., Eisen, G.M., Peters, D., Morris, C.D., Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA 300 (2008), 1417–1422.
56. 3 Lieberman, D., Moravec, M., Holub, J., Michaels, L., Eisen, G., Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. Gastroenterology 135 (2008), 1100–1105.
57. 4 Lash, R.H., Genta, R.M., Schuler, C.M., Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol 63 (2010), 681–686.
58. 5 Clinical Outcomes Research Initiative, 2007. Available at: www.cori.org. Accessed December 7, 2013.
59. 6 Johns, L.E., Houlston, R.S., A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 96 (2001), 2992–3003.
60. 7 Lindgren, G., Liljegren, A., Jaramillo, E., Rubio, C., Lindblom, A., Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut 50 (2002), 228–234.
61. 8 Cottet, V., Pariente, A., Nalet, B., et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology 133 (2007), 1086–1092.
62. 9 Lynch, K.L., Ahnen, D.J., Byers, T., Weiss, D.G., Lieberman, D.A., First-degree relatives of patients with advanced colorectal adenomas have an increased prevalence of colorectal cancer. Clin Gastroenterol Hepatol 1 (2003), 96–102.
63. 10 Ben, Q., An, W., Jiang, Y., et al. Body mass index increases risk for colorectal adenomas based on meta-analysis. Gastroenterology 142 (2012), 762–772.
64. 11 Okabayashi, K., Ashrafian, H., Hasegawa, H., et al. Body mass index category as a risk factor for colorectal adenomas: a systematic review and meta-analysis. Am J Gastroenterol 107 (2012), 1175–1185.
65. 12 Larsson, S.C., Wolk, A., Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 86 (2007), 556–565.
66. 13 Tsoi, K.K., Pau, C.Y., Wu, W.K., Chan, F.K., Griffiths, S., Sung, J.J., Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 7 (2009), 682–688.e1-5.
67. 14 Botteri, E., Iodice, S., Raimondi, S., Maisonneuve, P., Lowenfels, A.B., Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 134 (2008), 388–395.
68. 15 Liang, P.S., Chen, T.Y., Giovannucci, E., Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer 124 (2009), 2406–2415.
69. 16 Mizoue, T., Inoue, M., Tanaka, K., et al. Tobacco smoking and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 36 (2006), 25–39.
70. 17 Eddi, R., Karki, A., Shah, A., DeBari, V.A., DePasquale, J.R., Association of type 2 diabetes and colon adenomas. J Gastrointest Cancer 43 (2012), 87–92.
71. 18 He, J., Stram, D.O., Kolonel, L.N., Henderson, B.E., Le Marchand, L., Haiman, C.A., The association of diabetes with colorectal cancer risk: the Multiethnic Cohort. Br J Cancer 103 (2010), 120–126.
72. 19 Kim, B.C., Shin, A., Hong, C.W., et al. Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control 23 (2012), 727–735.
73. 20 Wong, P., Weiner, M.G., Hwang, W.T., Yang, Y.X., Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiol Biomarkers Prev 21 (2012), 1833–1840.
74. 21 Yuhara, H., Steinmaus, C., Cohen, S.E., Corley, D.A., Tei, Y., Buffler, P.A., Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. Am J Gastroenterol 106 (2011), 1911–1922.
75. 22 Cole, B.F., Logan, R.F., Halabi, S., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101 (2009), 256–266.
76. 23 Grodstein, F., Newcomb, P.A., Stampfer, M.J., Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106 (1999), 574–582.
77. 24 Erhardt, J.G., Kreichgauer, H.P., Meisner, C., Bode, J.C., Bode, C., Alcohol, cigarette smoking, dietary factors and the risk of colorectal adenomas and hyperplastic polyps—a case control study. Eur J Nutr 41 (2002), 35–43.
78. 25 Morimoto, L.M., Newcomb, P.A., Ulrich, C.M., Bostick, R.M., Lais, C.J., Potter, J.D., Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential?. Cancer Epidemiol Biomarkers Prev 11 (2002), 1012–1018.
79. 26 Potter, J.D., Bigler, J., Fosdick, L., et al. Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiol Biomarkers Prev 8 (1999), 69–75.
80. 27 Martinez, M.E., McPherson, R.S., Levin, B., Glober, G.A., A case-control study of dietary intake and other lifestyle risk factors for hyperplastic polyps. Gastroenterology 113 (1997), 423–429.
81. 28 Hassan, C., Pickhardt, P.J., Marmo, R., Choi, J.R., Impact of lifestyle factors on colorectal polyp detection in the screening setting. Dis Colon Rectum 53 (2010), 1328–1333.
82. 29 Longacre, T.A., Fenoglio-Preiser, C.M., Mixed hyperplastic adenomatous polyps/serrated adenomas: a distinct form of colorectal neoplasia. Am J Surg Pathol 14 (1990), 524–537.
83. 30 Spring, K.J., Zhao, Z.Z., Karamatic, R., et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 131 (2006), 1400–1407.
84. 31 Jorgensen, O.D., Kronborg, O., Fenger, C., A randomized surveillance study of patients with pedunculated and small sessile tubular and tubulovillous adenomas: the Funen Adenoma Follow-up Study. Scand J Gastroenterol 30 (1995), 686–692.
85. 32 Hixson, L.J., Fennerty, M.B., Sampliner, R.E., McGee, D.L., Garewal, H., Two-year incidence of colon adenomas developing after tandem colonoscopy. Am J Gastroenterol 89 (1994), 687–691.
86. 33 Wegener, M., Borsch, G., Schmidt, G., Colorectal adenomas: distribution, incidence of malignant transformation, and rate of recurrence. Dis Colon Rectum 29 (1986), 383–387.
87. 34 Yamaji, Y., Watabe, H., Goichi, T., et al. Heterogeneity in growth speed of colorectal adenomas. Gastroenterology 124 (2003), 608–614.
88. 35 Hofstad, B., Vatn, M., Larsen, S., Osnes, M., Growth of colorectal polyps: recovery and evaluation of unresected polyps of less than 10 mm, 1 year after detection. Scand J Gastroenterol 29 (1994), 640–645.
89. 36 Hofstad, B., Almendingen, K., Vatn, M., et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion 59 (1998), 148–156.
90. 37 Hofstad, B., Vatn, M., Growth rate of colon polyps and cancer. Gastrointest Endosc Clin N Am 7 (1997), 345–363.
91. 38 Hofstad, B., Vatn, M., Hoff, G., Larsen, S., Osnes, M., Growth of colorectal polyps: design of a prospective, randomized, placebo-controlled intervention study in patients with colorectal polyps. Eur J Cancer Prev 1 (1992), 415–422.
92. 39 Hofstad, B., Vatn, M., Larsen, S., Huitfeldt, H.S., Osnes, M., In situ measurement of colorectal polyps to compare video and fiberoptic endoscopes. Endoscopy 26 (1994), 461–465.
93. 40 Hofstad, B., Vatn, M., Larsen, S., Osnes, M., Reliability of in situ measurements of colorectal polyps. Scand J Gastroenterol 27 (1992), 59–64.
94. 41 Hofstad, B., Vatn, M.H., Andersen, S.N., et al. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut 39 (1996), 449–456.
95. 42 Gurudu, S.R., Heigh, R.I., De Petris, G., et al. Sessile serrated adenomas: demographic, endoscopic and pathological characteristics. World J Gastroenterol 16 (2010), 3402–3405.
96. 43 Lazarus, R., Junttila, O.E., Karttunen, T.J., Makinen, M.J., The risk of metachronous neoplasia in patients with serrated adenoma. Am J Clin Pathol 123 (2005), 349–359.
97. 44 Chandra, A., Sheikh, A.A., Cerar, A., Talbot, I.C., Clinico-pathological aspects of colorectal serrated adenomas. World J Gastroenterol 12 (2006), 2770–2772.
98. 45 Sandmeier, D., Seelentag, W., Bouzourene, H., Serrated polyps of the colorectum: is sessile serrated adenoma distinguishable from hyperplastic polyp in a daily practice?. Virchows Arch 450 (2007), 613–618.
99. 46 Anderson, J.C., Rangasamy, P., Rustagi, T., et al. Risk factors for sessile serrated adenomas. J Clin Gastroenterol 45 (2011), 694–699.
100. 47 Yamaji, Y., Mitsushima, T., Ikuma, H., et al. Right-side shift of colorectal adenomas with aging. Gastrointest Endosc 63 (2006), 453–458.
101. 48 Greene, F.L., Distribution of colorectal neoplasms: a left to right shift of polyps and cancer. Am Surg 49 (1983), 62–65.
102. 49 Huang, C.S., O'Brien, M.J., Yang, S., Farraye, F.A., Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. Am J Gastroenterol 99 (2004), 2242–2255.
103. 50 Shinya, H., Wolff, W.I., Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg 190 (1979), 679–683.
104. 51 Butterly, L.F., Chase, M.P., Pohl, H., Fiarman, G.S., Prevalence of clinically important histology in small adenomas. Clin Gastroenterol Hepatol 4 (2006), 343–348.
105. 52 Kim, D.H., Pickhardt, P.J., Taylor, A.J., Characteristics of advanced adenomas detected at CT colonographic screening: implications for appropriate polyp size thresholds for polypectomy versus surveillance. AJR Am J Roentgenol 188 (2007), 940–944.
106. 53 O'Brien, M.J., Winawer, S.J., Zauber, A.G., et al. The National Polyp Study: patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 98 (1990), 371–379.
107. 54 Muto, T., Bussey, H.J., Morson, B.C., The evolution of cancer of the colon and rectum. Cancer 36 (1975), 2251–2270.
108. 55 Villavicencio, R.T., Rex, D.K., Colonic adenomas: prevalence and incidence rates, growth rates, and miss rates at colonoscopy. Semin Gastrointest Dis 11 (2000), 185–193.
109. 56 Odom, S.R., Duffy, S.D., Barone, J.E., Ghevariya, V., McClane, S.J., The rate of adenocarcinoma in endoscopically removed colorectal polyps. Am Surg 71 (2005), 1024–1026.
110. 57 Church, J.M., Clinical significance of small colorectal polyps. Dis Colon Rectum 47 (2004), 481–485.
111. 58 Rennert, G., Rennert, H.S., Miron, E., Peterburg, Y., Population colorectal cancer screening with fecal occult blood test. Cancer Epidemiol Biomarkers Prev 10 (2001), 1165–1168.
112. 59 Gupta, A.K., Melton, L.J. III, Petersen, G.M., et al. Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study. Clin Gastroenterol Hepatol 3 (2005), 150–158.
113. 60 Lieberman, D.A., Weiss, D.G., Bond, J.H., Ahnen, D.J., Garewal, H., Chejfec, G., Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperative Study Group 380. N Engl J Med 343 (2000), 162–168.
114. 61 Lansdorp-Vogelaar, I., van Ballegooijen, M., Boer, R., Zauber, A., Habbema, J.D., A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer 115 (2009), 2410–2419.
115. 62 Pox, C.P., Altenhofen, L., Brenner, H., Theilmeier, A., Von Stillfried, D., Schmiegel, W., Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 142 (2012), 1460–1467.e2.
116. 63 Brenner, H., Chang-Claude, J., Seiler, C.M., Rickert, A., Hoffmeister, M., Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 154 (2011), 22–30.
117. 64 Ladabaum, U., Levin, Z., Mannalithara, A., Brill, J.V., Bundorf, M., Colorectal testing utilization and payments in a large cohort of commercially insured US adults. Am J Gastroenterol 109 (2014), 1513–1525.
118. 65 Ness, R.M., Holmes, A.M., Klein, R., Dittus, R., Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 94 (1999), 1650–1657.